The following is an edited excerpt.
The Supreme Court on Thursday issued a ruling that bans the patenting of naturally occurring genes but allows edited or artificially created DNA to be patented. What does the decision mean for patients and the biotech industry? We talked to experts about some of the big takeaways:
- Naturally occurring genes are no longer patentable.
- Synthetic DNA is still fair game.
- Prices for testing genetic diseases are already falling.
- It could get easier to sequence whole genomes.
- There are implications beyond human genes.
- Whether Myriad’s secret patient database will be opened is unclear.
- The ruling might not actually matter that much.
Read the full story here: 7 Takeaways From Supreme Court’s Gene Patent Decision